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Future developments will include the design of a
small portable system of N.A.A. which will make pos-
sible the study of tissue levels in hospitals or places
of work. This will comprise a plutonium-beryllium
source of neutrons together with a small, modem
detector system which should be sufficiently compact
to fit into a car.
We thank Dr R. G. Adams, Dr J. D. Blainey, Dr J. F.
Harrison, Dr J. B. Hawkins, and Dr G. E. Owen-Williams for
referring cases for study, and D. Vartsky, E. E. Cartwright,
F. R. Stewart, and M. R. Hawksworth for technical help.
Radiation health aspects of the study were approved by the
United Birmingham Hospitals Ethical Committee. Cadaver
studies were done with the help of Prof. J. T. Eayrs’ depart-
ment and with the permission of H.M. Inspector of Anatomy,
and necropsy samples were supplied by Prof. R. C. Curran.
Urine cadmium levels were determined by Mr E. King, Depart-
ment of Occupational Hygiene, Manchester.
Requests for reprints should be addressed to T. C. H.,
Department of Medicine, Queen Elizabeth Hospital, Birming-
ham B 15 2TM.
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POSSIBLE PATHOGENIC ROLE OF
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Summary Evidence of circulating endotoxin was
sought in children with Reye’s syn-
drome, on the thesis that severe hepatic failure is
likely to result in loss of capacity to detoxify intestinal
endotoxins entering the circulation. A modification
of the Limulus assay was used to demonstrate high
levels of endotoxin-like activity (E.L.A.) in nine coma-
tose patients with Reye’s syndrome and in one of the
two non-comatose patients. The symptom-free sib-
ling of one patient had raised liver enzymes and a
negative Limulus test. Plasma E.L.A. correlated sig-
nificantly with degree of electroencephalographic dis-
turbance early in the course of the illness. E.L.A.
was also found in both of two cerebrospinal fluids
evaluated. Preliminary in-vitro characterisation of
this substance indicated that it resembled endotoxin
derived from anaerobic intestinal bacteria. Intestin-
ally derived endotoxin could be one factor in the
pathogenesis of encephalopathy and other features of
Reye’s syndrome.
* Present address: Department of Child Health, School of Medicine,
University of Missouri, Columbia, Missouri 65201, U.S.A.
Introduction
FIRST described in 1963,1 Reye’s syndrome-acute
encephalopathy with fatty degeneration of the viscera
-is a severe and often fatal disease of unknown
aetiology and pathogenesis. Brain damage in this dis-
ease may result from failure of a damaged liver to
inactivate potentially encephalotoxic substances, such
as ammonia.2 However, no single toxin has been
unequivocally implicated as the cause of encephalo-
pathy associated with hepatic failure.3.4
Under normal conditions, intestinal bacterial anti-
gens, including endotoxins derived from the gram-
negative flora, may regularly be released into the
circulation in small quantities; this release increases
sharply under a variety of stress conditions.5,6 The
Limulus assay has been used to demonstrate endo-
toxin-like substance in the plasma of patients with
fulminant hepatic failure due to conditions other than
Reye’s syndrome,’ and we have used this test to search
for endotoxin-like activity (E.L.A.) in plasma and
cerebrospinal fluid of children with Reye’s syndrome.
Patients and Methods
Patients
Reye’s syndrome was diagnosed if the patient became
comatose or showed greatly altered consciousness after a
period of protracted vomiting, lacked focal neurologic
signs, had raised serum transaminases and ammonia with
little or no jaundice, had normal cerebrospinal-fluid cell-
counts and protein, and had no additional diagnosis. E.L.A.
was measured in eleven children with Reye’s syndrome and
in controls. Ten of the patients presented during an
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outbreak of influenza B in February and March, 1974;
the eleventh was recovering from varicella when the
syndrome developed. ’
Endotoxin Assay
E.L.A. in plasma was’ estimated with the Limulus test
of Levin and Bang.s A lysate of the blood-cells of the
horseshoe crab (L. polyphemus) was prepared according
to the method of Yin et al.9 and buffered with 0-1 OM
" tris ". Blood-samples were obtained under aseptic con-
ditions with pyrogen-free syringes (Becton-Dickinson Co.,
Rutherford, New Jersey) and were anticoagulated with
50 units per ml. beef-lung heparin (Upjohn Co.,
Kalamazoo, Michigan). All glassware was rendered
pyrogen-free by heating at 170&deg;C for 4 hours.
A previously unreported method of extracting Limulus
test inhibitors from plasma was used. Plasma samples
were diluted 1/3 in pyrogen-free water (Travenol Labora-
tories, Deerfield, Illinois) and heated at 100&deg;C for 10
minutes. Comparative preliminary experiments in our
laboratory suggested that this method was less cumber-
some than chloroform extraction 10 and more effective than
a method utilising shifts in pH 11 After heating, the
plasma was further diluted in serial log or half-log incre-
ments ; 25 ju,l. samples of these dilutions were incubated
with equal volumes of Limulus lysate for 4 hours at 37’C
and overnight at 22*C, and then examined for the
appearance of a viscous gel. Each day’s run included
a fresh plasma sample from a healthy adult control,
pyrogen-free water alone, and serial dilutions of a standard
endotoxin (Escherichia coli 0 26 B6 Boivin endotoxin,
control no. 586784, Difco, Detroit). Plasma E.L.A. was
estimated by comparing activity of plasma dilutions with
the standard endotoxin controls. This method detects
10 pg. per ml. of the standard endotoxin in normal
plasma. In some instances, extracted samples were
also treated with prolonged heating, with polymyxin B,
or with chloroform before testing. Spinal-fluid samples
were tested in serial dilution without prior extraction.
Results
Nine patients became fully comatose during their
illness. Among twenty plasma samples obtained from
these patients during the first 5 days of central-
nervous-system illness, E.L.A. ranged between 1 and
3000 ng. per ml. with a mean of 30 ng. per ml. Five
of these patients were studied sequentially (fig. 1).
Fig. 1-Sequential plasma E.L.A. in five patients with Reye’s
syndrome.
E.L.A. fell during the first few days after onset of encephalopathy.
In two patients, E.L.A. remained detectable long after resolution
of coma.
Declining levels were associated with clinical improve-
ment in three. In the two fatal cases, E.L.A. decreased
only on appearance of ante-mortem E.E.G. patterns
(electrocerebral silence or near-silence). The E.L.A.
concentration in one survivor rose again for several
days without clinical signs of relapse.
Two patients exhibited delirium and ataxia but did
not become comatose. Both were sampled during the
first day of improvement in central-nervous-system
symptoms. Plasma-E.L.A. levels were 30 ng. per ml.
Fig. 2-Correlates of plasma E.L.A. in children with Reye’s
syndrome.
E.L.A. was significantly correlated with: (a) Polymorphonuclear-
cell count (p.M.N.) (n=21, r=0-58, r < 0-01). (b) Serum-
phosphorus depression (n=20, r=0-43, r<005). (c) Electro-
encephalographic (E.E.G.) stage (Aoki and Lombroso) in patients
tested during the first 4 days of central-nervous-system illness
who had not reached E.E.G. silence (n=14, r=0-63, P<001).
Shaded areas show normal ranges.
and undetectable (<0-01 ng. per ml.). In addition,
the sibling of one of our patients had raised liver en-
zymes but no clinical symptoms; his plasma Limulus
test was also negative. Control samples were donated
by ward personnel each day that patient samples were
drawn; these were run simultaneously with patient
samples and were uniformly negative.
Plasma Limulus activity was not correlated with
body temperature, liver-enzyme levels, or platelet-
count. No patient had significant hypotension when
studied. Polymorphonuclear neutrophil-count was
significantly related to E.L.A., however (fig. 2a). E.L.A.
was also related to serum-phosphorus depression
(fig. 2b).
Fourteen electroencephalograms were done within
24 hours of E.L.A. sampling. These were scored by
the criteria of Aoki and Lombroso 12 without know-
ledge of patients’ clinical condition or E.L.A. These
criteria include five grades of abnormality in addition
to electrocerebral silence, and were shown to have
prognostic significance in patients with Reye’s syn-
drome. There was a positive relationship between
plasma E.L.A. and electroencephalographic abnormality
among patients in the first 4 days of central-nervous-
system illness who had not reached electrocerebral
silence (fig. 2c).
Two spinal-fluid samples were obtained for study;
both had E.L.A. The first was from a conscious,
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recuperating patient and contained 0.01 ng. per ml.
activity; a simultaneous plasma sample was not
obtained. The second was from a comatose patient
and contained 1-0 ng. per ml., while simultaneous
plasma level was 300 ng. per ml. In both instances
spinal-fluid glucose, protein, and cell-count were
normal.
Preliminary attempts to characterise the E.L.A. were
made on a few samples. Activity was unaltered by
heating at 100&deg;C for 60 minutes, by vigorous extrac-
tion of the samples with chloroform for 15 minutes,
or by incubation at 37&deg;C for 15 minutes in the pre-
sence of 10 /g. per ml. polymyxin B. Simultaneous
experiments demonstrated that these findings were
also characteristic of Bacteroides fragilis s.sp. vulgatus
endotoxin (kindly provided by V. R. Dowell, Center
for Disease Control, Atlanta, Georgia).
Discussion
We found the new method of extracting plasma
inhibitors in the Limulus test to be effective and con-
venient, and it should improve the utility of the test
as a clinical research tool. The test can be done on
as little as 50 ju.l. plasma.
We found E.L.A. in the plasma and cerebrospinal
fluid of children with Reye’s syndrome, and endotoxin-
like activity was related to clinical and electroencepha-
lographic indices of central-nervous-system disability
early in the course of the disease, suggesting that the
endotoxin may be encephalopathogenic during this
phase. The brain may be very sensitive to small
amounts of endotoxin reaching it 13,14; one prominent
early response to intraventricular endotoxin is hyper-
ventilation with respiratory alkalosis 15 Other mani-
festations of endotoxin activity include the release
of endogenous vasoactive mediators,16 fever," hacmor-
rhagic effects,18 granulocytosis,l mitochondrial swell-
ing with paralysis of oxidative phosphorylation,19 and
increase of free fatty acids with hepatic dysfunction
and triglyceride accumulation." These features,
demonstrated largely in animals and animal tissues,
have all been theoretically implicated in the patho-
genesis of Reye’s syndrome.
We have measured endotoxin activity in twelve
patients with gram-negative septicaemia but no evi-
dence of severe hepatic disease (unpublished). This
group, which included six babies, had a mean peak
level of 1 ng. per ml. (range 0-100) compared with
30 ng. per ml. (range 1-3000) found among comatose
patients with Reye’s syndrome. This suggests that
the levels found in children with Reye’s syndrome are
very high, although the two groups are not strictly
comparable since different extraction techniques were
used for many plasma samples in the earlier study.
There is no irrefutable evidence that E.L.A. in
patients with Reye’s syndrome or hepatic failure 7
is due to endotoxin. However, our preliminary in-
vitro experiments demonstrating its chloroform insolu-
bility and resistance to chloroform or 100&deg;C heat
denaturation are compatible with that possibility.
Resistance to polymyxin was also a property of this
substance; the only known endotoxin with this
characteristic is that produced by B. f ragilis, a find-
ing we have confirmed. The correlation of E.L.A.
with neutrophil-count is compatible with bone-
marrow response to bacterial endotoxin. Limulus
reactivity of bioactive substances such as polyribo-
nucleotides has been claimed.22
To our knowledge, hypophosphatxmia with Reye’s
syndrome has not previously been described. In our
series, endotoxaemia, hypophosphataemia, and electro-
encephalographic abnormality were statistically corre-
lated. A renal tubular loss of phosphate secondary
to the proximal tubular lesion described in Reye’s
syndrome 1 could be postulated.
We do not know whether the encephalopathy in
children with Reye’s syndrome is primary or results
from severe hepatic failure. However, our findings
suggest the latter, since positive Limulus tests, like
raised blood-ammonia levels, are linked with the
encephalopathy of fulminant hepatic failure from
causes other than Reye’s syndrome.’ In addition, the
E.L.A., which is very possibly due to enteric endotoxin,
could contribute to the encephalopathy as well as
other features of Reye’s syndrome, and deserves further
evaluation as such.
Our findings support the view that efforts to con-
trol gut flora in patients with acute, reversible hepatic
failure should be directed towards anaerobic as well
as aerobic intestinal flora. Anaerobic organisms are
largely resistant to aminoglycosides such as neo-
mycin,23 yet they are potentially a source of many
toxic substances, including ammonia and endotoxin.
Requests for reprints should be addressed to M. S. C.
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